News Madrigal eyes combination MASH therapy with Pfizer deal Madrigal Pharma is reheating a drug for metabolic dysfunction-associated steatohepatitis (MASH) put on ice by Pfizer last year.
News Madrigal closes on EU approval of first MASH treatment Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a MASH treatment.
News Madrigal Pharma is first over the MASH finish line Madrigal Pharma has become the first drugmaker to claim FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH), an elusive target that ha
News NHS "isn't delivering equitable care for rare diseases" A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.